Menu Search
Equities

Grail Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NL0:FRA

Grail Inc

Actions
  • Price (EUR)77.00
  • Today's Change-5.20 / -6.33%
  • Shares traded5.00
  • 1 Year change+131.93%
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026 07:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

  • Revenue in USD (TTM)141.83m
  • Net income in USD-406.24m
  • Incorporated2020
  • Employees1.00k
  • Location
    Grail Inc1525 O'brien DriveMENLO PARK 94025United StatesUSA
  • Phone+1 (650) 771-9796
  • Fax+1 (302) 655-5049
  • Websitehttps://grail.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.